![Thomas Bergh](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 6 M $ al 31/05/2026
Thomas Bergh is currently a Director at nWise AB, Oncorena Holding AB, Nwise ägare AB, and Animal Probiotics Sweden AB. He is also currently serving as an Investment Manager at MedCap AB (Private Equity) since 2016 and as the Chief Financial Officer at Linc AB since 2020.
Previously, he worked as a Director at Cardiolex Medical AB and Morgan Stanley AB. From 2016 to 2020, he was an Investment Manager at MedCap AB. Mr. Bergh holds a graduate degree and an MBA from Stockholm School of Economics.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
LINC AB 1,38 % | 31/12/2025 | 800.000 ( 1,38 % ) | 6 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| LINC AB | Director Financiero/CFO | 01/01/2020 |
MedCap AB (Private Equity)
 MedCap AB (Private Equity) Investment ManagersFinance MedCap concentrates on investments in the Nordic region as well as in Europe, with a short- or medium-term outlook. The firm targets debt-free SMEs with substantial development potential and valued up to SEK 200 million, or having SEK 50 to 200 million in turnover. They target annual returns on each investment of at least 20 percent. MedCap typically acquires majority stakes in their portfolio companies. They may also take minority stakes, with a minimum of 20 percent. Their portfolio is generally composed of eight to ten firms. They are active investors. They provide experience and access to networks along with expansion capital when necessary. Their targeted investment horizon is five to seven years. MedCap also aims to consolidate the life science market in the Nordic region. To this end, they consider merging ownership to form more robust organizations, as well as collaborating on sales, and product development. They have invested in areas such as technical aids for persons with disabilities, healthcare technologies, systems for vacuum electrodes for ECG, micro-technology and miniaturized separation science, tissue engineering to develop functional substitutes for damaged tissues, and pharmacological solutions for treatment of nicotine addiction. | Inversor de Capital Privado | 01/02/2016 |
nWise AB
 nWise AB Packaged SoftwareTechnology Services Develops communication apps and provides telecom relay services | Director/Miembro de la Junta | - |
Oncorena Holding AB
 Oncorena Holding AB Pharmaceuticals: MajorHealth Technology Develops novel pharmacological treatment for metastasing clear cell renal cancer | Director/Miembro de la Junta | - |
Nwise ägare AB | Director/Miembro de la Junta | - |
Animal Probiotics Sweden AB | Director/Miembro de la Junta | - |
| Empresas | Cargo | Fin |
|---|---|---|
| MEDCAP AB | Director de Inversiones | 01/01/2020 |
Cardiolex Medical AB
 Cardiolex Medical AB Medical SpecialtiesHealth Technology Develops and markets the vacuum ECG for fixation of ECG electrodes | Director/Miembro de la Junta | - |
Morgan Stanley AB
 Morgan Stanley AB Investment ManagersFinance Provides wealth management and investment banking services | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 10 |
|---|---|
MedCap AB
 MedCap AB Medical SpecialtiesHealth Technology Manufactures and sells radiological & ECG equipment, probiotics and nutritional supplements | Health Technology |
Stockholm School of Economics
 Stockholm School of Economics Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cardiolex Medical AB
Cardiolex Medical AB Medical SpecialtiesHealth Technology Develops and markets the vacuum ECG for fixation of ECG electrodes | Health Technology |
MedCap AB (Private Equity)
MedCap AB (Private Equity) Investment ManagersFinance MedCap concentrates on investments in the Nordic region as well as in Europe, with a short- or medium-term outlook. The firm targets debt-free SMEs with substantial development potential and valued up to SEK 200 million, or having SEK 50 to 200 million in turnover. They target annual returns on each investment of at least 20 percent. MedCap typically acquires majority stakes in their portfolio companies. They may also take minority stakes, with a minimum of 20 percent. Their portfolio is generally composed of eight to ten firms. They are active investors. They provide experience and access to networks along with expansion capital when necessary. Their targeted investment horizon is five to seven years. MedCap also aims to consolidate the life science market in the Nordic region. To this end, they consider merging ownership to form more robust organizations, as well as collaborating on sales, and product development. They have invested in areas such as technical aids for persons with disabilities, healthcare technologies, systems for vacuum electrodes for ECG, micro-technology and miniaturized separation science, tissue engineering to develop functional substitutes for damaged tissues, and pharmacological solutions for treatment of nicotine addiction. | Finance |
Morgan Stanley AB
Morgan Stanley AB Investment ManagersFinance Provides wealth management and investment banking services | Finance |
nWise AB
nWise AB Packaged SoftwareTechnology Services Develops communication apps and provides telecom relay services | Technology Services |
Oncorena Holding AB
Oncorena Holding AB Pharmaceuticals: MajorHealth Technology Develops novel pharmacological treatment for metastasing clear cell renal cancer | Health Technology |
Linc AB
 Linc AB Financial ConglomeratesFinance Invests and develops small and medium-sized product-oriented life science companies | Finance |
Nwise ägare AB | |
Animal Probiotics Sweden AB |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
